Harriet Ware

Harriet Ware

Auto-generated profile, based on publicly available information

Harriet Ware

Centre for Health Informatics, Department of Community Health Sciences, University of Calgary, Calgary, AB, Canada

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2022 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
IBIsabel Bergeri
Isabel Bergeri
MWMairead G. Whelan
Mairead G. Whelan
HWHarriet Ware
Harriet Ware
LSLorenzo Subissi
Lorenzo Subissi
ANAnthony Nardone
Anthony Nardone
UGUnity Studies Collaborator Group
Unity Studies Collaborator Group
Background: Our understanding of the global scale of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection remains incomplete: Routine surveillance data underestimate infection and cannot infer on population immunity; there is a predominance of asymptomatic infections, and uneven access to diagnostics. We meta-analyzed SARS-CoV-2 seroprevalence studies, standardized to those described in the World Health Organization’s Unity protocol (WHO Unity) for general population seroepidemiological studies, to estimate the extent of population infection and seropositivity to the virus 2 years into the pandemic. Methods and findings: We conducted a systematic review and meta-analysis, searching MEDLINE, Embase, Web of Science, preprints, and grey literature for SARS-CoV-2 seroprevalence published between January 1, 2020 and May 20, 2022. The review protocol is registered with PROSPERO (CRD42020183634). We included general population cross-sectional and cohort studies meeting an assay quality threshold (90% sensitivity, 97% specificity; exceptions for humanitarian settings). We excluded studies with an unclear or closed population sample frame. Eligible studies—those aligned with the WHO Unity protocol—were extracted and critically appraised in duplicate, with risk of bias evaluated using a modified Joanna Briggs Institute checklist. We meta-analyzed seroprevalence by country and month, pooling to estimate regional and global seroprevalence over time; compared seroprevalence from infection to confirmed cases to estimate underascertainment; meta-analyzed differences in seroprevalence between demographic subgroups such as age and sex; and identified national factors associated with seroprevalence using meta-regression. We identified 513 full texts reporting 965 distinct seroprevalence studies (41% low- and middle-income countries [LMICs]) sampling 5,346,069 participants between January 2020 and April 2022, including 459 low/moderate risk of bias studies with national/subnational scope in further analysis. By September 2021, global SARS-CoV-2 seroprevalence from infection or vaccination was 59.2%, 95% CI [56.1% to 62.2%]. Overall seroprevalence rose steeply in 2021 due to infection in some regions (e.g., 26.6% [24.6 to 28.8] to 86.7% [84.6% to 88.5%] in Africa in December 2021) and vaccination and infection in others (e.g., 9.6% [8.3% to 11.0%] in June 2020 to 95.9% [92.6% to 97.8%] in December 2021, in European high-income countries [HICs]). After the emergence of Omicron in March 2022, infection-induced seroprevalence rose to 47.9% [41.0% to 54.9%] in Europe HIC and 33.7% [31.6% to 36.0%] in Americas HIC. In 2021 Quarter Three (July to September), median seroprevalence to cumulative incidence ratios ranged from around 2:1 in the Americas and Europe HICs to over 100:1 in Africa (LMICs). Children 0 to 9 years and adults 60+ were at lower risk of seropositivity than adults 20 to 29 (p < 0.001 and p = 0.005, respectively). In a multivariable model using prevaccination data, stringent public health and social measures were associated with lower seroprevalence (p = 0.02). The main limitations of our methodology include that some estimates were driven by certain countries or populations being overrepresented. Conclusions: In this study, we observed that global seroprevalence has risen considerably over time and with regional variation; however, over one-third of the global population are seronegative to the SARS-CoV-2 virus. Our estimates of infections based on seroprevalence far exceed reported Coronavirus Disease 2019 (COVID-19) cases. Quality and standardized seroprevalence studies are essential to inform COVID-19 response, particularly in resource-limited regions.

23 August 2022 in BMJ Global Health
Verified
Journal Article
Open access
PDF file
HLHannah C Lewis
Hannah C Lewis
HWHarriet Ware
Harriet Ware
MWMairead Whelan
Mairead Whelan
LSLorenzo Subissi
Lorenzo Subissi
ZLZihan Li
Zihan Li
IBIsabel Bergeri
Isabel Bergeri
Introduction Estimating COVID-19 cumulative incidence in Africa remains problematic due to challenges in contact tracing, routine surveillance systems and laboratory testing capacities and strategies. We undertook a meta-analysis of population-based seroprevalence studies to estimate SARS-CoV-2 seroprevalence in Africa to inform evidence-based decision making on public health and social measures (PHSM) and vaccine strategy. Methods We searched for seroprevalence studies conducted in Africa published 1 January 2020–30 December 2021 in Medline, Embase, Web of Science and Europe PMC (preprints), grey literature, media releases and early results from WHO Unity studies. All studies were screened, extracted, assessed for risk of bias and evaluated for alignment with the WHO Unity seroprevalence protocol. We conducted descriptive analyses of seroprevalence and meta-analysed seroprevalence differences by demographic groups, place and time. We estimated the extent of undetected infections by comparing seroprevalence and cumulative incidence of confirmed cases reported to WHO.PROSPERO: CRD42020183634. Results We identified 56 full texts or early results, reporting 153 distinct seroprevalence studies in Africa. Of these, 97 (63%) were low/moderate risk of bias studies. SARS-CoV-2 seroprevalence rose from 3.0% (95% CI 1.0% to 9.2%) in April–June 2020 to 65.1% (95% CI 56.3% to 73.0%) in July–September 2021. The ratios of seroprevalence from infection to cumulative incidence of confirmed cases was large (overall: 100:1, ranging from 18:1 to 954:1) and steady over time. Seroprevalence was highly heterogeneous both within countries—urban versus rural (lower seroprevalence for rural geographic areas), children versus adults (children aged 0–9 years had the lowest seroprevalence)—and between countries and African subregions. Conclusion We report high seroprevalence in Africa suggesting greater population exposure to SARS-CoV-2 and potential protection against COVID-19 severe disease than indicated by surveillance data. As seroprevalence was heterogeneous, targeted PHSM and vaccination strategies need to be tailored to local epidemiological situations.

1 March 2025 in Annals of Internal Medicine
Verified
Journal Article
Closed access
CCChristian Cao
Christian Cao
JSJason Sang
Jason Sang
RARohit Arora
Rohit Arora
DCDavid Chen
David Chen
RKRobert Kloosterman
Robert Kloosterman
NBNiklas Bobrovitz
Niklas Bobrovitz
Systematic reviews (SRs) are hindered by the initial rigorous article screen, which delays access to reliable information synthesis. To develop generic prompt templates for large language model (LLM)-driven abstract and full-text screening that can be adapted to different reviews. Diagnostic test accuracy. 48 425 citations were tested for abstract screening across 10 SRs. Full-text screening evaluated all 12 690 freely available articles from the original search. Prompt development used the GPT4-0125-preview model (OpenAI). None. Large language models were prompted to include or exclude articles based on SR eligibility criteria. Model outputs were compared with original SR author decisions after full-text screening to evaluate performance (accuracy, sensitivity, and specificity). Optimized prompts using GPT4-0125-preview achieved a weighted sensitivity of 97.7% (range, 86.7% to 100%) and specificity of 85.2% (range, 68.3% to 95.9%) in abstract screening and weighted sensitivity of 96.5% (range, 89.7% to 100.0%) and specificity of 91.2% (range, 80.7% to 100%) in full-text screening across 10 SRs. In contrast, zero-shot prompts had poor sensitivity (49.0% abstract, 49.1% full-text). Across LLMs, Claude-3.5 (Anthropic) and GPT4 variants had similar performance, whereas Gemini Pro (Google) and GPT3.5 (OpenAI) models underperformed. Direct screening costs for 10 000 citations differed substantially: Where single human abstract screening was estimated to require more than 83 hours and $1666.67 USD, our LLM-based approach completed screening in under 1 day for $157.02 USD. Further prompt optimizations may exist. Retrospective study. Convenience sample of SRs. Full-text screening evaluations were limited to free PubMed Central full-text articles. A generic prompt for abstract and full-text screening achieving high sensitivity and specificity that can be adapted to other SRs and LLMs was developed. Our prompting innovations may have value to SR investigators and researchers conducting similar criteria-based tasks across the medical sciences. None.

15 December 2021 in medRxiv
Verified
Preprint
Open access
PDF file
IBIsabel Bergeri
Isabel Bergeri
MWMairead Whelan
Mairead Whelan
HWHarriet Ware
Harriet Ware
LSLorenzo Subissi
Lorenzo Subissi
ANAnthony Nardone
Anthony Nardone
MKMaria Van Kerkhove
Maria Van Kerkhove
Background: Our understanding of the global scale of SARS-CoV-2 infection remains incomplete: routine surveillance data underestimates infection and cannot infer on population immunity, there is a predominance of asymptomatic infections, and uneven access to diagnostics. We meta-analyzed SARS-CoV-2 seroprevalence studies, standardized to those described in WHO’s Unity protocol for general population seroepidemiological studies, two years into the pandemic, to estimate the extent of population infection and remaining susceptibility. Methods and Findings: We conducted a systematic review and meta-analysis, searching MEDLINE, Embase, Web of Science, preprints, and grey literature for SARS-CoV-2 seroprevalence published between 2020-01-01 and 2022-05-20. The review protocol is registered with PROSPERO, (CRD42020183634). We included general population cross-sectional and cohort studies meeting an assay quality threshold (90% sensitivity, 97% specificity; exceptions for humanitarian settings). We excluded studies with an unclear or closed population sample frame. Eligible studies - those aligned with the WHO Unity protocol - were extracted and critically appraised in duplicate, with Risk of Bias evaluated using a modified Joanna Briggs Institute checklist. We meta-analyzed seroprevalence by country and month, pooling to estimate regional and global seroprevalence over time; compared seroprevalence from infection to confirmed cases to estimate under-ascertainment; meta-analyzed differences in seroprevalence between demographic subgroups such as age and sex; and identified national factors associated with seroprevalence using meta-regression. The main limitations of our methodology include that some estimates were driven by certain countries or populations being over-represented. We identified 513 full texts reporting 965 distinct seroprevalence studies (41% LMIC) sampling 5,346,069 participants between January 2020 and April 2022, including 459 low/moderate risk of bias studies with national/sub-national scope in further analysis. By September 2021, global SARS-CoV-2 seroprevalence from infection or vaccination was 59.2%, 95% CI [56.1-62.2%]. Overall seroprevalence rose steeply in 2021 due to infection in some regions (e.g., 26.6% [24.6-28.8] to 86.7% [84.6-88.5%] in Africa in December 2021) and vaccination and infection in others (e.g., 9.6% [8.3-11.0%] to 95.9% [92.6-97.8%] in Europe high-income countries in December 2021). After the emergence of Omicron, infection-induced seroprevalence rose to 47.9% [41.0-54.9%] in EUR HIC and 33.7% [31.6-36.0%] in AMR HIC in March 2022. In 2021 Quarter Three (July to September), median seroprevalence to cumulative incidence ratios ranged from around 2:1 in the Americas and Europe HICs to over 100:1 in Africa (LMICs). Children 0-9 years and adults 60+ were at lower risk of seropositivity than adults 20-29 ( p <0.0001 and p =0.005, respectively). In a multivariable model using pre-vaccination data, stringent public health and social measures were associated with lower seroprevalence ( p =0.02). Conclusions: In this study, we observed that global seroprevalence has risen considerably over time and with regional variation, however around 40 % of the global population remains susceptible to SARS-CoV-2 infection. Our estimates of infections based on seroprevalence far exceed reported COVID-19 cases. Quality and standardized seroprevalence studies are essential to inform COVID-19 response, particularly in resource-limited regions.

13 June 2025 in medRxiv
Verified
Preprint
Open access
PDF file
CCChristian Cao
Christian Cao
RARohit Arora
Rohit Arora
PCPaul Cento
Paul Cento
ABAdil Budak
Adil Budak
KMKatherine Manta
Katherine Manta
IBIsabelle Boutron
Isabelle Boutron
Importance: Systematic reviews (SRs) inform evidence-based decision making. Yet, many take over a year to complete, are labor intensive, prone to human error, and face reproducibility challenges; thus limiting access to timely and reliable information. Objective: To validate a large language model (LLM)-based workflow (otto-SR) to automate three of the most labour intensive tasks in performing SR’s: article screening, data extraction, and risk of bias assessment; and to assess its feasibility in rapidly updating existing reviews. Design, setting, and participants: We conducted a validation study in four phases, with direct benchmarking against graduate-level human researchers in phases 1 and 2. Phase 1: article screening performance was measured across 32,357 citations from 5 systematic reviews. The reference standard consisted of the original reviews’ screening decisions after full-text screening. Phase 2: data extraction performance was measured across 4,495 data points from 495 studies in 7 reviews. Phase 3: risk of bias assessment (ROB2, Newcastle-Ottawa, QUADAS2) performance was measured across 345 studies from 12 reviews. Reference standards for Phase 2 and Phase 3 were created after blinded adjudication of the original review extraction and RoB assessments. Phase 4: otto-SR was used to reproduce and update the primary analysis from an issue of Cochrane reviews (n=12 reviews, 146,276 citations), with analytical comparisons to the original meta-analyzed findings. All discrepancies underwent dual human review. Results: otto-SR showed high performance in phase 1 article screening ( otto-SR : 96.7% sensitivity, 97.9% specificity; human: 81.7% sensitivity, 98.1% specificity) and phase 2 data extraction ( otto-SR : 93.1% accuracy; human: 79.7% accuracy). In phase 3, otto-SR demonstrated high interrater reliability for risk of bias judgements (ROB2 0.98, Newcastle-Ottawa 0.95, QUADAS2 0.74; Gwet AC2). In phase 4, otto-SR , reproduced and updated the primary analysis from an issue of Cochrane reviews. Across Cochrane reviews, otto-SR incorrectly excluded a median of 0 studies (IQR 0 to 0.25), and found nearly twice as many eligible studies compared to the original authors (n= 114 vs. 64). Meta-analyses based on otto-SR generated screening and extraction outputs, subsequently verified through dual human review, yielded newly statistically significant effect estimates in 2 reviews and negated significance in 1 review. Conclusions and relevance: LLMs have high performance in article screening, data extraction, and risk of bias assessments. They can rapidly reproduce and update existing systematic reviews, laying the foundation for automated, scalable, and reliable evidence synthesis.

15 February 2022 in medRxiv
Verified
Preprint
Open access
PDF file
HLHc Lewis
Hc Lewis
HWH Ware
H Ware
MWM Whelan
M Whelan
LSLorenzo Subissi
Lorenzo Subissi
ZLZ Li
Z Li
TGthe UNITY Studies Collaborator Group
the UNITY Studies Collaborator Group
Introduction Estimating COVID-19 cumulative incidence in Africa remains problematic due to challenges in contact tracing, routine surveillance systems and laboratory testing capacities and strategies. We undertook a meta-analysis of population-based seroprevalence studies to estimate SARS-CoV-2 seroprevalence in Africa to inform evidence-based decision making on Public Health and Social Measures (PHSM) and vaccine strategy. Methods We searched for seroprevalence studies conducted in Africa published 01-01-2020 to 30-12-2021 in Medline, Embase, Web of Science, and Europe PMC (preprints), grey literature, media releases and early results from WHO Unity studies. All studies were screened, extracted, assessed for risk of bias and evaluated for alignment with the WHO Unity protocol for seroepidemiological investigations. We conducted descriptive analyses of seroprevalence and meta-analysed seroprevalence differences by demographic groups, place and time. We estimated the extent of undetected infections by comparing seroprevalence and cumulative incidence of confirmed cases reported to WHO. PROSPERO: CRD42020183634. Results We identified 54 full texts or early results, reporting 151 distinct seroprevalence studies in Africa Of these, 95 (63%) were low/moderate risk of bias studies. SARS-CoV-2 seroprevalence rose from 3.0% [95% CI: 1.0-9.2%] in Q2 2020 to 65.1% [95% CI: 56.3-73.0%] in Q3 2021. The ratios of seroprevalence from infection to cumulative incidence of confirmed cases was large (overall: 97:1, ranging from 10:1 to 958:1) and steady over time. Seroprevalence was highly heterogeneous both within countries - urban vs. rural (lower seroprevalence for rural geographic areas), children vs. adults (children aged 0-9 years had the lowest seroprevalence) - and between countries and African sub-regions (Middle, Western and Eastern Africa associated with higher seroprevalence). Conclusion We report high seroprevalence in Africa suggesting greater population exposure to SARS-CoV-2 and protection against COVID-19 disease than indicated by surveillance data. As seroprevalence was heterogeneous, targeted PHSM and vaccination strategies need to be tailored to local epidemiological situations.